WallStreetZenWallStreetZen

NASDAQ: SGTX
Sigilon Therapeutics Inc Stock

$0.66-0.04 (-5.71%)
Updated Jan 27, 2023
SGTX Price
$0.66
Fair Value Price
$1.72
Market Cap
$21.42M
52 Week Low
$0.29
52 Week High
$2.08
P/E
-0.39x
P/B
0.48x
P/S
1.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.29M
Earnings
-$54.62M
Gross Margin
100%
Operating Margin
-426.97%
Profit Margin
-444.4%
Debt to Equity
1.13
Operating Cash Flow
-$62M
Beta
1.16
Next Earnings
Mar 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A

SGTX Overview

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SGTX ($0.66) is undervalued by 61.54% relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SGTX ($0.66) is significantly undervalued by 61.54% relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SGTX due diligence checks available for Premium users.

Be the first to know about important SGTX news, forecast changes, insider trades & much more!

SGTX News

Valuation

SGTX fair value

Fair Value of SGTX stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$1.72
Undervalued by
61.54%
SGTX ($0.66) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SGTX ($0.66) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SGTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.39x
Industry
12.89x
Market
23.59x

SGTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
5.18x
SGTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SGTX's financial health

Profit margin

Revenue
$4.3M
Net Income
-$8.7M
Profit Margin
-203.9%
SGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SGTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$94.6M
Liabilities
$50.2M
Debt to equity
1.13
SGTX's short-term assets ($80.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGTX's short-term assets ($80.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.0M
Investing
$8.3M
Financing
$13.0k
SGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SGTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SGTX$21.42M-5.71%-0.39x0.48x
DOMH$21.39M+1.83%-1.01x0.26x
TPST$21.45M+1.49%-0.78x0.80x
EFTR$21.32M+5.60%0.42x1.84x
FBRX$21.21M0.00%-1.31x0.50x

Sigilon Therapeutics Stock FAQ

What is Sigilon Therapeutics's quote symbol?

NASDAQ: SGTX) Sigilon Therapeutics trades on the NASDAQ under the ticker symbol SGTX. Sigilon Therapeutics stock quotes can also be displayed as NASDAQ: SGTX.

If you're new to stock investing, here's how to buy Sigilon Therapeutics stock.

What is the 52 week high and low for Sigilon Therapeutics (NASDAQ: SGTX)?

(NASDAQ: SGTX) Sigilon Therapeutics's 52-week high was $2.08, and its 52-week low was $0.29. It is currently -68.27% from its 52-week high and 127.59% from its 52-week low.

How much is Sigilon Therapeutics stock worth today?

(NASDAQ: SGTX) Sigilon Therapeutics currently has 32,456,737 outstanding shares. With Sigilon Therapeutics stock trading at $0.66 per share, the total value of Sigilon Therapeutics stock (market capitalization) is $21.42M.

Sigilon Therapeutics stock was originally listed at a price of $34.78 in Dec 4, 2020. If you had invested in Sigilon Therapeutics stock at $34.78, your return over the last 2 years would have been -98.1%, for an annualized return of -86.22% (not including any dividends or dividend reinvestments).

How much is Sigilon Therapeutics's stock price per share?

(NASDAQ: SGTX) Sigilon Therapeutics stock price per share is $0.66 today (as of Jan 27, 2023).

What is Sigilon Therapeutics's Market Cap?

(NASDAQ: SGTX) Sigilon Therapeutics's market cap is $21.42M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sigilon Therapeutics's market cap is calculated by multiplying SGTX's current stock price of $0.66 by SGTX's total outstanding shares of 32,456,737.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.